NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Kura Oncology, Inc. (KURA) Stock Analysis

Kura Oncology, Inc. (KURA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

KURA

$9.88

−$0.10 (−1.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KURA with… →

KURA Key Statistics

As of Oct 21, 2026
Trading
Open
$10.05
Previous Close
$9.98
Day's Range
9.85–10.18
52-Week Range
7.36–13.90
Volume
1.16M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.47
Valuation
Market Cap
$878.93M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
11.38
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.37
Financials (FY)
Revenue (FY)
$67.48M+25.24%
Net Income (FY)
−$278.67M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
88.96M
1-Year Return
+3.13%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
1.85M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, KURA closed at $9.88, +3.13% over 1 year.

Kura Oncology, Inc. (KURA) has a market capitalization of $878.93M.

In fiscal 2025, KURA reported revenue of $67.48M.

KURA Stock Return by Calendar Year

Kura Oncology, Inc. (KURA) 10-year return: what $10,000 became

1 year
$10,000 $10,313
+3.13%
5 years
$10,000 $5,652
−43.48%
10 years
$10,000 $18,296
+82.96%

If you had invested $10,000 in Kura Oncology, Inc. (KURA) 10 years ago, at the close on October 21, 2016, it would have been worth $18,296 at the close on October 21, 2026: +82.96% in total, +6.23% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−4.91%
2025+19.29%
2024−39.43%
2023+15.87%
2022−11.36%
2021−57.13%
2020+137.53%
2019−2.07%
2018−8.24%
2017+159.32%
2016 (partial year)+46.04%

As of October 21, 2026.

KURA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$67.48M−$278.67M−412.9%
2024$53.88M−$173.98M−322.9%
2023$0.00−$152.63M—
2022$0.00−$135.84M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$67.48M$67.43M−$303.63M−$278.67M−412.9%
2024$53.88M$53.88M−$193.20M−$173.98M−322.9%
2023$0.00$0.00−$165.80M−$152.63M—
2022$0.00—−$139.87M−$135.84M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KURA Valuation vs Biotechnology Median

Median of 608 stocks
MetricKURABiotechnology medianvs median
P/S ratio11.3813.3014% below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Kura Oncology, Inc. (KURA) is capitalised at $878.93M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 260.

KURA last closed at $9.88 on October 21, 2026. That is −$0.10 (−1.00%) against the previous close. The 52-week range on file runs from $7.36 to $13.90. The latest close sits 34.28% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $67.48M. Against the prior fiscal year total of $53.88M, that is a change of +25.24%. The same year closed with a net loss of $278.67M. Earnings per share on a trailing basis come to −3.37.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $67.48M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 11.38. On price-to-sales that is 14.42% below the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is +3.13%. Across 10 years the annualized return works out at +6.23%. The reported beta is 0.47. Daily returns over the trailing 10 years annualize to a volatility of 68.43%.

Growth & Income

No dividend is on file for KURA.

So far in 2026 the total return is −4.91%. Across the complete calendar years on file, 2017 returned +159.32% and 2021 returned −57.13%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Kura Oncology, Inc. (KURA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Kura Oncology, Inc. KURA $878.93M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Kura Oncology, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Kura Oncology, Inc.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Visit website →